Expansion Opportunity Recent acquisition of NIRLAB Sarl signals geographic and capability expansion. Engage with integration teams and target cross-sell opportunities for MX908 and VipIR capabilities to broaden analytical reach in Europe and adjacent markets.

New Capabilities Launch of MX908 mass spectrometry capabilities and VipIR handheld analyser highlights a push into rapid, on-site identification of unknown substances. Position to healthcare, emergency response, and security clients with fast, actionable results to address fentanyl, narcotics, and hazardous substances.

Regulatory & Compliance Fentanyl analog classifier and trace chemical identification features address high-stakes compliance and safety needs. Target government, defense, and regulated industries that require defensible, auditable on-site analytics for critical risk mitigation.

Financial Signals Revenue trajectory is positive with quarterly revenue around mid-teens millions and ongoing profitability challenges. Focus on enterprise customers with higher unit volumes and service contracts to improve unit economics and reduce customer churn.

Strategic Partnerships Portfolio combines hardware, software automation, and machine learning. Create joint pilots with distributors, labs, and safety agencies to demonstrate end-to-end analyses, data workflows, and recurring software updates that deepen stickiness.